Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Net Margin (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Net Margin for 4 consecutive years, with 124.62% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin fell 7010.0% year-over-year to 124.62%, compared with a TTM value of 71.55% through Sep 2025, up 20331.0%, and an annual FY2024 reading of 0.07%, up 322081.0% over the prior year.
  • Net Margin was 124.62% for Q3 2025 at Atara Biotherapeutics, down from 13.58% in the prior quarter.
  • Across five years, Net Margin topped out at 241.96% in Q4 2022 and bottomed at 8966.96% in Q2 2023.
  • Average Net Margin over 4 years is 1633.88%, with a median of 91.29% recorded in 2024.
  • The sharpest move saw Net Margin tumbled -148171bps in 2023, then surged 890045bps in 2024.
  • Year by year, Net Margin stood at 241.96% in 2022, then plummeted by -612bps to 1239.75% in 2023, then surged by 118bps to 221.71% in 2024, then tumbled by -156bps to 124.62% in 2025.
  • Business Quant data shows Net Margin for ATRA at 124.62% in Q3 2025, 13.58% in Q2 2025, and 38.73% in Q1 2025.